An End-of-study Subgroup Analysis of Black Patients From the Phase 2 GRIFFIN (AFT-29) Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM)
- Citation:
- Blood vol 140 (suppl 1) 10154–6
- Meeting Instance:
- ASH 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3685
- Pharmas:
- Janssen
- Grants:
- Corr. Author:
- Authors:
- Ajay K. Nooka Jonathan L. Kaufman Cesar Rodriguez Andrzej Jakubowiak Yvonne Efebera Brandi Reeves Tanya M. Wildes Sarah A. Holstein Larry D. Anderson Jr. Ashraf Badros Leyla Shune Ajai Chari Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Shira Dinner Paul G. Richardson Saad Z Usmani Peter Voorhees
- Networks:
- KANSAS, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, MD015, NC002, NE003, OH008
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: